By Senad KaraahmetovicBank of America analyst Alec Stranahan initiated research coverage on Novavax (NASDAQ:NVAX) with an Underperform rating and a $35.00 per share price...
If the FDA committee endorses Novavax's shot, the drug regulator is almost certain to rapidly authorize it for use in the U.S.
TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co said on Wednesday its 12-month operating profit slid 9.5%, although the country's largest drugmaker forecast a rebound for the...
While many COVID-era tech stock favorites are struggling as the world returns to normal, the crypto market has overall remained strong since the pandemic's onset in early 2020.Key...
Pre-commercial biotech group Novavax’s stock is down more than 45% in January.The FDA has not yet authorized Novavax’s vaccine for use in the US.Long-term investors...
Moderna (NASDAQ:MRNA)’s MRNA stock has seemingly bucked its strong uptrend since August last year as investors await another success from its pipeline. The stock has gained...
Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Buy | Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Neutral | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 94.48 | 95.09 | 86.73 | +12.17 | +14.79% | 45.63M | NYSE | |||
| 550.66 | 554.57 | 527.72 | +19.03 | +3.58% | 3.95M | NASDAQ | |||
| 236.70 | 239.43 | 234.52 | +4.09 | +1.76% | 947.58K | NYSE | |||
| 46.53 | 46.68 | 45.05 | +0.61 | +1.33% | 61.60K | OTC Markets | |||
| 41.93 | 42.17 | 38.82 | +3.62 | +9.45% | 11.22M | NASDAQ | |||
| 170.11 | 171.09 | 168.96 | +1.14 | +0.67% | 5.18M | NASDAQ | |||
| 58.11 | 58.27 | 55.58 | +2.33 | +4.18% | 4.06M | NYSE | |||
| 69.53 | 70.85 | 68.88 | -0.77 | -1.10% | 5.44M | NYSE | |||
| 1.95 | 1.95 | 1.70 | +0.280 | +16.77% | 43.63K | NASDAQ | |||
| 1.07 | 2.01 | 1.05 | -2.310 | -68.34% | 18.48M | NASDAQ | |||
| 57.94 | 58.10 | 57.31 | +0.48 | +0.84% | 91.53K | NYSE | |||
| 0.88 | 1.12 | 0.76 | +0.21 | +31.76% | 2.26M | NASDAQ | |||
| 2.83 | 3.30 | 2.70 | -0.36 | -11.29% | 550.45K | NYSE | |||
| 21.81 | 21.98 | 21.40 | +0.42 | +1.96% | 1.06M | NYSE | |||
| 4.75 | 4.95 | 4.688 | +0.045 | +0.96% | 10.79K | NASDAQ |